Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2851-2860

  Lee, Todd A ^a   Chang, Chun Lan ^b   Stephenson, Judith J ^b   Sajjan, Shiva G ^c   Maiese, Eric M ^c   Everett, Sharlette ^c   Allen Ramey, Felicia ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HEALTHCORE INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adherence; Asthma; Asthma control; Inhaled corticosteroids; Leukotrienes; Outcomes; Resource utilization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR AFFECTING AGENT;

ADULT; ARTICLE; ASTHMA; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-ASTHMATIC AGENTS; ASTHMA; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78349231593     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.531255     Document Type: Article

References (26)

1. Bahodori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:2
2. National Asthma Education and Prevention Program. Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. 2007. http:// www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf. [Last accessed 29 March, 2010]
3. Akinbami L. Asthma prevalence, health care use and mortality: United States, 2003-05. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
4. Web site. http://www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05. htm. [Last accessed March 28, 2010]
5. Sullivan SD, Rasouliyan L, Russo PA, et al. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62:126-33
6. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30
7. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95
8. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003;3:28-34
9. Pearson M, Barnes N, Thomas M, et al. Evaluating the effectiveness of asthma treatment in real-life practice. J Eval Clin Pract 2005; 10:297-305.
10. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-97
12. Dragomir A, Cô té R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical settings. Value Health 2010;13:87-94
13. Shenolikar RH, Balkrishnan R, Camacho FT, et al. Comparison of medication adherence and associated healthcare costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199-207
14. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures of patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001;23:1589-600
15. Mattke S, Matorell F, Yeon Hong S, et al. Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population. J Asthma 2010;47:323-9
16. Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675-84
17. Strunk RC, Sternberg AL, Szefler J, et al. Long-term budesonide or nedocro-mil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009;154:682-7
18. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63
19. Schatz M, Nakahiro R, Jones CH, et al. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care 2004;10:25-32
20. Williams LK, Pladevall M, Hi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288-93
21. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117:542-50
22. Bel EH, Clinical phenotypes of asthma. Curr Opin Pulm Med 2004;10:44-50
23. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999;130:487-95
24. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-18
25. Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: clinical implications. Curr Opin Pulm Med 2010;16:13-18
26. Stewart KA, Higgins PC, McLaughlin CG, et al. Differences in prevalence, treatment, and outcomes of asthma among a diverse population of children with equal access to care: findings from a study in the military health system. Arch Pediatr Adolesc Med 2010;164:720-6